These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 38460798)

  • 21. LncRNA MALAT1 promotes development of mantle cell lymphoma by associating with EZH2.
    Wang X; Sehgal L; Jain N; Khashab T; Mathur R; Samaniego F
    J Transl Med; 2016 Dec; 14(1):346. PubMed ID: 27998273
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Expression of MiR101 and EZH2 in Patients with Mantle Cell Lymphoma and Its Clinical Significance].
    Lin YL; Zou ZK; Su HY; Huang YQ
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2019 Jun; 27(3):820-826. PubMed ID: 31204938
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Whole genome copy number analysis in search of new prognostic biomarkers in first line treatment of mantle cell lymphoma. A study by the LYSA group.
    Le Bris Y; Magrangeas F; Moreau A; Chiron D; Guérin-Charbonnel C; Theisen O; Pichon O; Canioni D; Burroni B; Maisonneuve H; Thieblemont C; Oberic L; Gyan E; Pellat-Deceunynck C; Hermine O; Delfau-Larue MH; Tessoulin B; Béné MC; Minvielle S; Le Gouill S
    Hematol Oncol; 2020 Oct; 38(4):446-455. PubMed ID: 32472610
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Long-term outcomes and mutation profiling of patients with mantle cell lymphoma (MCL) who discontinued ibrutinib.
    Jain P; Kanagal-Shamanna R; Zhang S; Ahmed M; Ghorab A; Zhang L; Ok CY; Li S; Hagemeister F; Zeng D; Gong T; Chen W; Badillo M; Nomie K; Fayad L; Medeiros LJ; Neelapu S; Fowler N; Romaguera J; Champlin R; Wang L; Wang ML
    Br J Haematol; 2018 Nov; 183(4):578-587. PubMed ID: 30175400
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Multiparameter immunohistochemical analysis of the cell cycle proteins cyclin D1, Ki-67, p21WAF1, p27KIP1, and p53 in mantle cell lymphoma.
    Izban KF; Alkan S; Singleton TP; Hsi ED
    Arch Pathol Lab Med; 2000 Oct; 124(10):1457-62. PubMed ID: 11035575
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinicopathological features of primary diffuse large B-cell lymphoma of the central nervous system - strong EZH2 expression implying diagnostic and therapeutic implication.
    Guo S; Bai Q; Rohr J; Wang Y; Liu Y; Zeng K; Yu K; Zhang X; Wang Z
    APMIS; 2016 Dec; 124(12):1054-1062. PubMed ID: 27807891
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Concomitant 1p36 deletion and TNFRSF14 mutations in primary cutaneous follicle center lymphoma frequently expressing high levels of EZH2 protein.
    Gángó A; Bátai B; Varga M; Kapczár D; Papp G; Marschalkó M; Kuroli E; Schneider T; Csomor J; Matolcsy A; Bödör C; Szepesi Á
    Virchows Arch; 2018 Oct; 473(4):453-462. PubMed ID: 29858685
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mantle cell lymphoma-variant Richter syndrome: Detailed molecular-cytogenetic and backtracking analysis reveals slow evolution of a pre-MCL clone in parallel with CLL over several years.
    Klener P; Fronkova E; Berkova A; Jaksa R; Lhotska H; Forsterova K; Soukup J; Kulvait V; Vargova J; Fiser K; Prukova D; Alam M; Calvin Lenyeletse Maswabi B; Michalova K; Zemanova Z; Jancuskova T; Pekova S; Trneny M
    Int J Cancer; 2016 Nov; 139(10):2252-60. PubMed ID: 27407063
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mantle cell lymphomas with concomitant MYC and CCND1 breakpoints are recurrently TdT positive and frequently show high-grade pathological and genetic features.
    Aukema SM; Croci GA; Bens S; Oehl-Huber K; Wagener R; Ott G; Rosenwald A; Kluin PM; van den Berg E; Bosga-Bouwer AG; Hoogendoorn M; Hoster E; Bittmann I; Nagel I; Murga Penas EM; Kreuz M; Bausinger J; Belder W; Oschlies I; Dyer MJS; Jayne S; Siebert R; Klapper W
    Virchows Arch; 2021 Jul; 479(1):133-145. PubMed ID: 33528622
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Genetic heterogeneity and prognostic impact of recurrent ANK2 and TP53 mutations in mantle cell lymphoma: a multi-centre cohort study.
    Jeong S; Park YJ; Yun W; Lee ST; Choi JR; Suh C; Jo JC; Cha HJ; Jeong JY; Chang H; Cha YJ; Kim H; Park MJ; Song W; Cho EH; Jeong EG; Lee J; Park Y; Lee YS; Kim DJ; Lee HS
    Sci Rep; 2020 Aug; 10(1):13359. PubMed ID: 32770099
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Quantitative gene expression deregulation in mantle-cell lymphoma: correlation with clinical and biologic factors.
    Kienle D; Katzenberger T; Ott G; Saupe D; Benner A; Kohlhammer H; Barth TF; Höller S; Kalla J; Rosenwald A; Müller-Hermelink HK; Möller P; Lichter P; Döhner H; Stilgenbauer S
    J Clin Oncol; 2007 Jul; 25(19):2770-7. PubMed ID: 17563396
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Wedelolactone Targets EZH2-mediated Histone H3K27 Methylation in Mantle Cell Lymphoma.
    Romanchikova N; Trapencieris P
    Anticancer Res; 2019 Aug; 39(8):4179-4184. PubMed ID: 31366503
    [TBL] [Abstract][Full Text] [Related]  

  • 33. NOTCH Signaling in Mantle Cell Lymphoma: Biological and Clinical Implications.
    Deshotels L; Safa FM; Saba NS
    Int J Mol Sci; 2023 Jun; 24(12):. PubMed ID: 37373427
    [TBL] [Abstract][Full Text] [Related]  

  • 34. SOX11-negative Mantle Cell Lymphoma: Clinicopathologic and Prognostic Features of 75 Patients.
    Xu J; Wang L; Li J; Saksena A; Wang SA; Shen J; Hu Z; Lin P; Tang G; Yin CC; Wang M; Medeiros LJ; Li S
    Am J Surg Pathol; 2019 May; 43(5):710-716. PubMed ID: 30768440
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Genomic landscape and prognostic analysis of mantle cell lymphoma.
    Yang P; Zhang W; Wang J; Liu Y; An R; Jing H
    Cancer Gene Ther; 2018 Jun; 25(5-6):129-140. PubMed ID: 29755111
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Differential expression of enhancer of zeste homolog 2 (EZH2) protein in small cell and aggressive B-cell non-Hodgkin lymphomas and differential regulation of EZH2 expression by p-ERK1/2 and MYC in aggressive B-cell lymphomas.
    Tian X; Pelton A; Shahsafaei A; Dorfman DM
    Mod Pathol; 2016 Sep; 29(9):1050-7. PubMed ID: 27282353
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Genetic and prognostic analysis of blastoid and pleomorphic mantle cell lymphoma: a multicenter analysis in China.
    Yang P; Liu SZ; Li CY; Zhang WL; Wang J; Chen YT; Li S; Liu CL; Liu H; Cai QQ; Zhang W; Jing HM
    Ann Hematol; 2024 Jul; 103(7):2381-2391. PubMed ID: 38165416
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Epigenetic silencing of miR-26A1 in chronic lymphocytic leukemia and mantle cell lymphoma: Impact on EZH2 expression.
    Kopparapu PK; Bhoi S; Mansouri L; Arabanian LS; Plevova K; Pospisilova S; Wasik AM; Croci GA; Sander B; Paulli M; Rosenquist R; Kanduri M
    Epigenetics; 2016 May; 11(5):335-43. PubMed ID: 27052808
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Longer-term follow-up and outcome by tumour cell proliferation rate (Ki-67) in patients with relapsed/refractory mantle cell lymphoma treated with lenalidomide on MCL-001(EMERGE) pivotal trial.
    Goy A; Kalayoglu Besisik S; Drach J; Ramchandren R; Robertson MJ; Avivi I; Rowe JM; Herbrecht R; Van Hoof A; Zhang L; Cicero S; Fu T; Witzig T
    Br J Haematol; 2015 Aug; 170(4):496-503. PubMed ID: 25921098
    [TBL] [Abstract][Full Text] [Related]  

  • 40. An immunohistochemical panel of insulin-like growth factor II mRNA-binding protein 3 (IMP3), enhancer of zeste homolog 2 (EZH2), and p53 is useful for a diagnosis in bile duct biopsy.
    Sasaki M; Sato Y
    Virchows Arch; 2021 Oct; 479(4):697-703. PubMed ID: 34115196
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.